rMark Bio Appoints Industry Thought Leaders and Executives to Advisory Board

Internationally recognized leaders in commercial analytics, enterprise data services and medical devices join rMark Bio to accelerate growth in pharmaceutical companies and new markets.

CHICAGO, Aug. 19, 2020 /PRNewswire/ — rMark Bio, a leader in the application of AI to accelerate innovation, collaboration, and scientific discovery for the life sciences industry, today announced the formation of its new Advisory Board. This new Advisory Board will help lead rMark Bio through its current global market expansion in commercial analytics, data services, medical affairs and devices. The Advisory Board consist of:

• Mark Niemaszek. Mr. Niemaszek is an experienced pharmaceutical professional with more than 30 years of financial and operations experience. Mr. Niemaszek had a successful career at Astellas Pharma as the Vice President of Commercial Operations, where he developed the company’s domestic and global commercial operations capabilities. Mr. Niemaszek is joining rMark Bio’s Advisory Board to accelerate adoption of the AI platform in commercial sales and analytics teams. Upon joining rMark Bio’s Advisory Board, Mr. Niemaszek stated, “I am excited to join rMark Bio’s Advisory Board. rMark Bio is a cutting-edge organization that has been able to utilize artificial intelligence to develop impactful solutions to medical affairs organizations. I hope to provide commercial insights to rMark Bio’s management team to expand their AI expertise for potential commercial solutions. rMark Bio has an experienced team that understands the issues facing manufacturers and is utilizing their expertise to develop answers that will improve efficiency and effectiveness.”
• Patrick Retif. Mr. Retif is a senior executive with more than 25 years of experience building and leading global business and technology organizations. In 2018, Mr. Retif was recruited by IQVIA to serve as the SVP/GM of the US Technology Solutions business. Prior to IQVIA, Mr. Retif spent eight years with Allergan where he served in multiple executive roles leading the global commercial IT organization and all technology services supporting 12,000+ commercial users across 75 country markets. Mr. Retif is joining rMark Bio’s Advisory Board to accelerate adoption of the AI platform and data services for commercial, medical affairs and R&D departments. Upon joining the Advisory Board, Mr. Retif stated, “I am excited to join rMark Bio’s Advisory Board. rMark Bio is uniquely positioned to bring true digital transformation to Medical Affairs organizations. Cue is an impressive application that leverages a proprietary and innovative AI technology. It magically brings all needed information at the fingertips of MSLs, strengthening their customer engagements through automated and intelligent scientific discovery. The capability and power of Fabric, the underlying AI platform, has many potentials in Life Sciences. I look forward to leveraging my background and experience to help apply Fabric to many other areas.”
• Philip Rackliffe. Mr. Rackliffe has 20+ years of global healthcare leadership and executive management in medical device/technology and pharmaceutical industries across both public and private sectors. Mr. Rackliffe is currently the CEO of Centerline Biomedical, a spin-off of Cleveland Clinic. Mr. Rackliffe will be joining rMark Bio’s Advisory Board to help accelerate the adoption of rMark’s Cue solution to Medical Device and Medical Affairs’ teams. After a recent demonstration of the Cue solution, Mr. Rackliffe noted, “I was blown away when I saw a demo of Cue. It solves numerous, critical unmet needs in the healthcare space across analytics and real-time data to drive business results and make sense of rich data from internal and external sources. I have been part of teams that have spent thousands of man hours trying to solve this Medical Affairs riddle, the team at rMark Bio has solved it.”
• Jeffrey A. Judd. With over 15 years of R&D, business strategy and IT delivery responsibility in the space, Mr. Judd has had the great fortune to work with both world class consultants and best-in-class companies. Mr. Judd was a founding employee at Veeva, where he worked in a strategic role to design and launch several early adopter programs with pharma customers while experiencing a period of hyper growth, as one of the true “unicorns” in the SaaS technology space. Mr. Judd will be joining rMark Bio’s Advisory Board to help advise on enterprise sales and delivery pipeline.

“I am excited and humbled to welcome these industry leaders to rMark Bio and augment our already strong leadership team,” said Jason M. Smith, CEO of rMark Bio. “We have a powerful AI platform designed for the life science industry that is poised to easily scale and solve the many unique business and data challenges across the industry. This new Advisory Board will help ensure we deliver to our full potential in this important next stage of our evolution.”

About rMark Bio

rMark Bio, Inc. was created to transform the life sciences industries by making artificial intelligence simple to adopt, easy to use and continuously transformative through a holistic approach incorporating strategy, technology and people power. Founded in 2015 by Jason M. Smith, CEO, and Lev Becker, Ph.D., Chief Scientist, rMark Bio is based in Chicago and Seattle. rMark Bio provides services to the top 20 pharmaceutical companies globally and has partnered with industry-leading technology and healthcare organizations, including West Monroe Partners, Microsoft, nVidia, Apigee/Google, and MATTER. Learn more about rMark Bio at www.rmarkbio.com.  

SOURCE rMark Bio Inc.